about
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularizationTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaTollip is a mediator of protein sumoylationStage-specific gene expression in early differentiating oligodendrocytes.Id1 restrains p21 expression to control endothelial progenitor cell formation.MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.Cadherin 6 is a new RUNX2 target in TGF-β signalling pathwayCadherin-6 promotes EMT and cancer metastasis by restraining autophagy.Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2.Novel therapeutic strategy in the management of COPD: a systems medicine approach.Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma.Contemporary and potential future molecular diagnosis of melanoma.Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer.Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood.Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.The extent of whole-genome copy number alterations predicts aggressive features in primary melanomas.Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas.Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN.BRAF V600E mutation and papillary thyroid cancer.Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.CDX2 expression in columnar variant of papillary thyroid carcinoma.Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs.Multiple Spitz naevi: the randomly distributed variant.High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.Lymph node melanocytic nevi: pathogenesis and differential diagnoses, with special reference to p16 reactivity.Molecular testing of thyroid fine-needle aspirations improves presurgical diagnosis and supports the histologic identification of minimally invasive follicular thyroid carcinomas.TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases.Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression.Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis.Role of CBX4 in the Colorectal Carcinoma Metastasis-Letter.
P50
Q24673319-DA6525B3-06D0-4BBD-839B-9BA371DFCDF1Q26853261-EAC8B9CE-C56D-4F63-9CF0-0D379FAAA0A9Q28569172-37CD056E-0C65-4267-9050-341959A6B88AQ30835844-13F478C8-13C5-4985-ACE3-1B03375423AEQ33311286-E52CF47E-8273-493A-AB0D-F9DABBAFE32FQ33704699-01440E47-0092-4EC7-A5B9-4B1E063C80F3Q34152070-3BAFDE7E-0989-405B-9F6E-453B3FC7FE89Q34999638-67CCA2FD-1EB9-42A6-AB51-A79BE57E34E5Q36067156-EDB02F10-DEA0-499F-92F4-21595B971607Q38380567-685EB4AA-F58E-4B52-A907-AC3317C9CFADQ38391415-2D6FCA28-9B6F-43FA-89B2-2993F1E03BCDQ38580151-2D7D2B52-155C-42BC-8B20-EC3BA2138F84Q38733534-4E0DA287-FEA2-4F84-8605-842634202D7DQ38847989-9C21B3DA-96E6-4373-8987-FC0151E0A556Q39032755-B919D630-451C-4DFC-B135-E92585A03FAFQ39426954-1E34BC34-AE2B-4A5F-9B16-BB1A9FD7BC30Q39621813-BF76F327-21BA-4092-BE8D-495EB59CBD20Q40228810-C809B9AE-FBA2-4730-BA58-87B101F4395AQ40314697-06C2B538-D38A-4041-9AC3-0ACBCE5A1B90Q42316246-EA82F69C-30A3-4333-B1DD-531A1C380980Q42533014-D483B2F7-3F5A-4829-9EF1-3789B7B54EA6Q43490603-EEF71684-7DA5-4624-A1A1-DC3809952B56Q47444118-E8BA562D-6C6E-4947-B87A-BC87E0E62AE9Q47692014-DDBF9013-0BE8-44E6-AB2C-E136E7C85053Q47832632-DED024DC-75AB-43AC-A58E-B13275CD2A90Q49197249-D32869BF-DF81-4CC6-B262-03D9DCC828BCQ50127595-4D97E9AE-5EEE-48B6-A6F4-7F1753A82D84Q50938750-015AAAA9-1527-4C2E-942B-1B3420A15D8FQ53003830-59F9AD43-EEA2-4C59-885C-3936B563771AQ53005229-68B76102-0FED-4B7F-9CE3-71E4DB6ECC94Q53142928-BB6FFB07-57AD-4C51-878A-9F0AF54BFBC0Q53438816-2F017866-791D-4012-A1FF-50AE3023C033Q53623530-EB55AD6E-1363-43C9-B1C9-473075245D74Q54176041-FAD9C925-446F-496A-97B1-3ED8329E86A0Q54297209-1CEC9882-ACCD-41F6-8EC8-E15531C748CDQ54328280-38A38282-DB6E-43C6-A077-A1E1ECE5B023Q54386381-29C030B0-4748-4BDD-9922-5423A027BB5EQ54469530-C7A30110-6339-4D40-8EF0-C4A508DAE450Q54476646-465F4CE4-6D2C-449B-897E-3735290F8CC4Q54599215-832AACC4-E47A-4E44-8F0A-F4949110657A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessia Ciarrocchi
@ast
Alessia Ciarrocchi
@en
Alessia Ciarrocchi
@es
Alessia Ciarrocchi
@nl
type
label
Alessia Ciarrocchi
@ast
Alessia Ciarrocchi
@en
Alessia Ciarrocchi
@es
Alessia Ciarrocchi
@nl
prefLabel
Alessia Ciarrocchi
@ast
Alessia Ciarrocchi
@en
Alessia Ciarrocchi
@es
Alessia Ciarrocchi
@nl
P106
P1153
14630134600
P21
P31
P496
0000-0002-5541-2075